Product Revenue Concentration Risk: The company's revenue is substantially dependent on sales of Firdapse (amifampridine), making it vulnerable to any factors that negatively impact its sales, such as increased competition, pricing pressures, or safety concerns.

Intense Market Competition Risk: The markets for LEMS and other neuromuscular or neurological disorders are highly competitive, with existing therapies and new treatments constantly emerging, which could limit Firdapse's market share or pricing power, and impact future pipeline products.

Clinical Development and Regulatory Failure Risk: Catalyst's future growth relies on the successful clinical development, regulatory approval, and commercialization of its product candidates, such as Fidanacant or CDP-101, a process that is lengthy, uncertain, and prone to failure at any stage.